CN101935346A - 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 - Google Patents
突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 Download PDFInfo
- Publication number
- CN101935346A CN101935346A CN 201010261030 CN201010261030A CN101935346A CN 101935346 A CN101935346 A CN 101935346A CN 201010261030 CN201010261030 CN 201010261030 CN 201010261030 A CN201010261030 A CN 201010261030A CN 101935346 A CN101935346 A CN 101935346A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- fibroblast growth
- fgf
- sudden change
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000030172 endocrine system disease Diseases 0.000 title claims abstract description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title abstract description 7
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title abstract description 7
- 229940126864 fibroblast growth factor Drugs 0.000 title abstract description 7
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims abstract description 46
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 16
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims abstract description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 230000008859 change Effects 0.000 claims description 36
- 210000004027 cell Anatomy 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 11
- 102000005431 Molecular Chaperones Human genes 0.000 claims description 8
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 102000044159 Ubiquitin Human genes 0.000 claims description 3
- 108090000848 Ubiquitin Proteins 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 102000035118 modified proteins Human genes 0.000 claims description 3
- 108091005573 modified proteins Proteins 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 238000005267 amalgamation Methods 0.000 claims description 2
- 238000010612 desalination reaction Methods 0.000 claims description 2
- 102000056713 human FGF21 Human genes 0.000 claims description 2
- 230000037356 lipid metabolism Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000006337 proteolytic cleavage Effects 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 241001465754 Metazoa Species 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 210000000601 blood cell Anatomy 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 210000001789 adipocyte Anatomy 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000003321 amplification Effects 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 241000219095 Vitis Species 0.000 description 6
- 235000009754 Vitis X bourquina Nutrition 0.000 description 6
- 235000012333 Vitis X labruscana Nutrition 0.000 description 6
- 235000014787 Vitis vinifera Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 4
- 108091006296 SLC2A1 Proteins 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- -1 Glurenor Chemical compound 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229940122069 Glycosidase inhibitor Drugs 0.000 description 1
- 208000009773 Insulin Coma Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040576 Shock hypoglycaemic Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003316 glycosidase inhibitor Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010261030XA CN101935346B (zh) | 2010-08-24 | 2010-08-24 | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010261030XA CN101935346B (zh) | 2010-08-24 | 2010-08-24 | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101935346A true CN101935346A (zh) | 2011-01-05 |
CN101935346B CN101935346B (zh) | 2012-08-08 |
Family
ID=43388938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010261030XA Active CN101935346B (zh) | 2010-08-24 | 2010-08-24 | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101935346B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603886A (zh) * | 2012-02-14 | 2012-07-25 | 东北农业大学 | 突变的成纤维细胞生长因子及在治疗内分泌疾病中的用途 |
CN103193878A (zh) * | 2013-04-03 | 2013-07-10 | 哈尔滨博翱生物医药技术开发有限公司 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
CN108866019A (zh) * | 2018-07-18 | 2018-11-23 | 青岛农业大学 | 一种重组肺炎链球菌二氢叶酸还原酶的制备方法及其应用 |
US20190367574A1 (en) * | 2017-03-22 | 2019-12-05 | Tasly Biopharmaceuticals Co., Ltd | Method of treating nash using a long-acting mutant human fibroblast growth factor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101250547A (zh) * | 2008-03-24 | 2008-08-27 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
WO2008121563A2 (en) * | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
-
2010
- 2010-08-24 CN CN201010261030XA patent/CN101935346B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008121563A2 (en) * | 2007-03-30 | 2008-10-09 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
CN101250547A (zh) * | 2008-03-24 | 2008-08-27 | 吉林农大生物反应器工程有限公司 | 人成纤维细胞生长因子-21的重组表达 |
Non-Patent Citations (1)
Title |
---|
《遗传》 20100630 候玉婷等 人FGF-21基因的克隆、表达及其调节脂肪细胞糖代谢的活性 583-587 1-10 第32卷, 第6期 2 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603886A (zh) * | 2012-02-14 | 2012-07-25 | 东北农业大学 | 突变的成纤维细胞生长因子及在治疗内分泌疾病中的用途 |
CN102603886B (zh) * | 2012-02-14 | 2013-08-07 | 东北农业大学 | 突变的成纤维细胞生长因子及在治疗ii型糖尿病中的用途 |
CN103193878A (zh) * | 2013-04-03 | 2013-07-10 | 哈尔滨博翱生物医药技术开发有限公司 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
CN103193878B (zh) * | 2013-04-03 | 2014-08-20 | 东北农业大学 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
US20190367574A1 (en) * | 2017-03-22 | 2019-12-05 | Tasly Biopharmaceuticals Co., Ltd | Method of treating nash using a long-acting mutant human fibroblast growth factor |
JP2020511545A (ja) * | 2017-03-22 | 2020-04-16 | 天士力生物医薬股▲フン▼有限公司Tasly Biopharmaceuticals Co., Ltd. | 長期作用型の変異ヒト由来線維芽細胞増殖因子の新規な用途 |
JP7491839B2 (ja) | 2017-03-22 | 2024-05-28 | 天士力生物医薬股▲フン▼有限公司 | 長期作用型の変異ヒト由来線維芽細胞増殖因子の新規な用途 |
CN108434441A (zh) * | 2018-04-17 | 2018-08-24 | 哈尔滨博翱生物医药技术开发有限公司 | 新型成纤维细胞生长因子-21类似物在治疗弥漫性间质性肺脏疾病中的应用 |
CN108866019A (zh) * | 2018-07-18 | 2018-11-23 | 青岛农业大学 | 一种重组肺炎链球菌二氢叶酸还原酶的制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101935346B (zh) | 2012-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102603886B (zh) | 突变的成纤维细胞生长因子及在治疗ii型糖尿病中的用途 | |
CN101935346B (zh) | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 | |
TWI667036B (zh) | 植物萃取物於調控pdgfc、fgf2、igf1r、ptgis、nos3、edn1、plat、proc、vwf、f3、serpine1、il-8、icam1、vcam1及casp8基因的用途 | |
CN103923207B (zh) | 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用 | |
CN106220724A (zh) | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 | |
CN106397607A (zh) | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 | |
CN101003574B (zh) | 长效降血糖肽的重组表达及其在糖尿病治疗药物中的应用 | |
CN106432509A (zh) | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 | |
CN113265007A (zh) | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 | |
CN1982336B (zh) | 一种人胰高血糖素样肽-1衍生物及其制备和应用 | |
CN102443064A (zh) | 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用 | |
CN108060195A (zh) | 一种发酵生产重组胰高血糖素样肽-1蛋白的方法 | |
CN112851791B (zh) | 一种新型抗代谢紊乱的fgf类似物及其应用 | |
CN100392070C (zh) | 表达人胰高血糖素样肽-1的基因工程菌及其构建方法和应用 | |
CN111388680B (zh) | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 | |
CN1978466B (zh) | 转导肽-人脑源性神经营养因子融合蛋白及其应用 | |
CN105884901B (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
CN102191207A (zh) | 表达可溶性fgf-21的基因工程菌及其构建方法和应用 | |
CN101824388A (zh) | 一种糖尿病食疗酵母及其构建方法 | |
CN102108097A (zh) | 一种新型glp-1衍生物 | |
CN101125883A (zh) | 重组vpac1受体特异激动剂rvpac1-a及其表达方法与应用 | |
CN105348380B (zh) | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 | |
CN101824423A (zh) | 一种融合基因gad-glp-1和糖尿病食疗型黄瓜的培育方法 | |
CN103613657B (zh) | 缩短肽链的Exendin4及其基因工程应用 | |
CN101544981A (zh) | 一种具有降血糖生物活性的苦瓜多肽基因工程制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: HARBIN BO'AO BIOPHARMACEUTICAL TECHNOLOGY DEVELOPM Free format text: FORMER OWNER: HARBIN HAKELONG BIOPHARMACEUTICAL INSTITUTE Effective date: 20120426 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 150009 HARBIN, HEILONGJIANG PROVINCE TO: 150030 HARBIN, HEILONGJIANG PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20120426 Address after: 314 room 150030, science and Technology Park, Northeast Agricultural University, 59 Wood Street, Xiangfang District, Heilongjiang, Harbin Applicant after: HARBIN BOAO BIOLOGICAL MEDICAL TECHNOLOGY DEVELOPMENT CO.,LTD. Address before: 150009, No. 3, building 203, building -1, building 32, Jianxin street, Nangang District, Heilongjiang, Harbin Applicant before: Harbin City Hakelong Biopharmaceutical Research Institute |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: NORTHEAST AGRICULTURAL UNIVERSITY Free format text: FORMER OWNER: HARBIN BO'AO BIOPHARMACEUTICAL TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20120716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Deshan Inventor after: Ren Guiping Inventor after: Gao Huashan Inventor after: Wang Wenfei Inventor after: Liu Mingyao Inventor before: Li Deshan Inventor before: Gao Huashan Inventor before: Ren Guiping Inventor before: Wang Wenfei Inventor before: Liu Mingyao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI DESHAN GAO HUASHAN REN GUIPING WANG WENFEI LIU MINGYAO TO: LI DESHAN REN GUIPING GAO HUASHAN WANG WENFEI LIU MINGYAO |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120716 Address after: 150030 Xiangfang City, Harbin Province Wood Street, No. 59, No. Patentee after: Northeast Agricultural University Address before: 314 room 150030, science and Technology Park, Northeast Agricultural University, 59 Wood Street, Xiangfang District, Heilongjiang, Harbin Patentee before: HARBIN BOAO BIOLOGICAL MEDICAL TECHNOLOGY DEVELOPMENT CO.,LTD. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20230522 Address after: 300410 2 East Road Puji River, Beichen District, Tianjin (Tsun Li modern Chinese medicine city) Patentee after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 150030 No. 59 Wood Street, Xiangfang District, Heilongjiang, Harbin Patentee before: Northeast Agricultural University |
|
TR01 | Transfer of patent right |